Shanghai Kaibao Pharmaceutical: Announcement regarding winning the second prize of the National Science and Technology Progress Award
Shanghai Kaibao Pharmaceutical: Legal Opinion of Tongli Law Firm in Shanghai on the Annual Shareholders Meeting of Shanghai Kaibao Pharmaceutical Co., Ltd. in 2023.
Shanghai Kaibao Pharmaceutical: Announcement of Resolutions of the Shareholders' Meeting for the Fiscal Year 2023
Shanghai Kaibao Pharmaceutical: Announcement on resignation of directors and by-election of directors
Shanghai Kaibao Pharmaceutical: Announcement on Additional Provisional Proposals for the 2023 Annual General Meeting of Shareholders and Supplementary Notice to the Shareholders' Meeting
Shanghai Kaibao Pharmaceutical: Announcement on the company's acquisition of a real estate title certificate
Shanghai Kaibao Pharmaceutical: Rules of Work for the Nomination Committee of the Board of Directors (April 2024)
Shanghai Kaibao Pharmaceutical: Foreign Investment Management System (April 2024)
Shanghai Kaibao Pharmaceutical: Board Remuneration and Assessment Committee Work Rules (April 2024)
Shanghai Kaibao Pharmaceutical: Board Strategy Committee Work Rules (April 2024)
Shanghai Kaibao Pharmaceutical: Rules of work for the Audit Committee of the Board of Directors (April 2024)
Shanghai Kaibao Pharmaceutical: Announcement on the revision and addition of company-related governance systems
Shanghai Kaibao Pharmaceutical: Special Meeting System for Independent Directors (April 2024)
Shanghai Kaibao Pharmaceutical: 2023 Financial Results Report
Shanghai Kaibao Pharmaceutical: 2023 Internal Control Self-Assessment Report
Shanghai Kaibao Pharmaceutical: Announcement on the use of idle own funds to entrust financial management limits
Shanghai Kaibao Pharmaceutical: 2023 Annual Report Disclosure Reminder
Shanghai Kaibao Pharmaceutical: 2023 Annual Financial Report
Shanghai Kaibao Pharmaceutical: Announcement on holding an online briefing on the 2023 annual results
Shanghai Kaibao Pharmaceutical: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
No Data